Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-1H plus Rituximab in Refractory/Relapsed Chronic Lymphoid Disorders
NCT00071396Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2002
- Primary completion
- Sep 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) and 4 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response at 4 weeks. Started Oct 2002; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)prolymphocytic leukemia (PLL)hairy cell leukemia (HCL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT00071396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071396.